

Drug Dosing in the Real World: Challenges and Opportunities

Issam Zineh, PharmD, MPH, FCP, FCCP Office of Clinical Pharmacology | Office of Translational Sciences | CDER | US FDA August 12, 2019

Acknowledgments

US FDA Office of Clinical Pharmacology

- Bernadette Johnson-Williams, Executive Program & Project Management Staff
- Rajanikanth (Raj) Madabushi, Guidance and Policy Team
- Yaning Wang, Division of Pharmacometrics
- Hao Zhu, Division of Pharmacometrics
- Qi Liu, Division of Clinical Pharmacology 5
- Robert Schuck, Genomics and Targeted Therapy Group
- Kimberly Bergman, Labeling and Health Communication


UNC Eshelman School of Pharmacy

- Dr. Bob Powell
- Dr. Daniel Gonzalez
- Dr. Herb Patterson
- Dr. Angela Kashuba

Contributors

Speakers, Moderators, and Panelists FDA CE Team Registrants and Participants

Precision Dosing – Key Questions



- What is precision dosing?
- What drugs are amenable to precision dosing?
- How big of a problem is "imprecise" dosing?
- What are the consequences?

• What are the barriers and enabling factors?

FDA

Is there a Public Health Need?


Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact

Daniel Gonzalez^{1,*}, Gauri G. Rao¹, Stacy C. Bailey², Kim L.R. Brouwer¹, Yanguang Cao¹, Daniel J. Crona^{1,3}, Angela D.M. Kashuba¹, Craig R. Lee¹, Kathryn Morbitzer⁴, J. Herbert Patterson¹, Tim Wiltshire¹, Jon Easter⁴, Scott W. Savage^{3,4} and J. Robert Powell¹

Clin Transl Sci (2017) 10, 443-454; doi:10.1111/cts.12490

Received: 7 March 2018 Revised and accepted: 7 May 2018
DOI: 10.1002/jac.5.1017
COLOR OF the American College of Clinical Pharmacy

CLINICAL PHARMACY FORUM



Natalie F. Pearce Pharm.D. ⁽³⁾ | Erika M. Giblin Pharm.D. | Catherine Buckthal Pharm.D. | Alana Ferrari Pharm.D. | J. Robert Powell Pharm.D. | Yanguang Cao Ph.D. | J. Herbert Patterson Pharm.D., FCCP

Why Has Model-Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future

AS Darwich¹, K Ogungbenro¹, AA Vinks^{2,3}, JR Powell⁴, J-L Reny^{5,6}, N Marsousi⁷, Y Daali^{5,7}, D Fairman⁸, J Cook⁹, LJ Lesko¹⁰, JS McCune¹¹, CAJ Knibbe¹², SN de Wildt^{13,14}, JS Leeder^{15,16}, M Neely¹⁷, AF Zuppa¹⁸, P Vicini¹⁹, L Aarons¹, TN Johnson²⁰, J Boiani²¹ and A Rostami-Hodjegan^{1,21}

The AAPS Journal (2019) 21: 17 DOI: 10.1208/s12248-018-0286-6

Meeting Report

What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing

Thomas M. Polasek,^{1,2,11}⁽⁶⁾ Amin Rostami-Hodjegan,^{1,3} Dong-Seok Yim,⁴ Masoud Jamei,¹ Howard Lee,^{5,6} Holly Kimko,⁷ Jae Kyoung Kim,⁸ Phuong Thi Thu Nguyen,^{9,10} Adam S. Darwich,³ and Jae-Gook Shin⁹

Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities

Ron J. Keizer^{1,*}, Rob ter Heine², Adam Frymoyer³, Lawrence J. Lesko⁴, Ranvir Mangat¹ and Srijib Goswami¹ CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 785–787; doi:10.1002/psp4.12353; published online on 16 October 2018.

Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development

Thomas M. Polasek^{1,2}, Craig R. Rayner^{1,2}, Richard W. Peck³, Andrew Rowland⁴, Holly Kimko⁵, and Amin Rostami-Hodjegan^{1,6}

Clinical Pharmacology in Drug Development 2019, 8(4) 418–425 © 2018, The American College of Clinical Pharmacology DOI: 10.1002/cpdd.638



CrossMark


What is Precision Dosing – Need for a Consensus Definition?



- <u>Aspirational</u>: Dosing that maximizes benefit/risk balance at the level of the individual patient
- <u>Practical</u>: Dosing that optimizes benefit/risk balance in subpopulations of patients
- Determinants of precision dosing:
 - Systems-related extrinsic >> intrinsic

Precision Dosing: Three Contexts for Consideration






Titration as a Therapeutic Individualization Strategy



- Uncertainty about optimal dosing (maximize efficacy and minimize safety risk) is a common reason for delay or denial of initial NDA approvals by the US FDA
- Response-guided titration may balance benefit/risk at the patient level
 - How frequently is this approach used?
 - How are titration regimens evaluated during drug development?
- Evaluated 181 drugs approved by US FDA from 2013-2017

Key Findings





Schuck 2019 [PMID 30791226]

Summary



- A minority of drugs approved from 2013–2017 (22%) included more than one dosing regimen in the prescription drug label
- Not all drugs are amenable to RGT (54%)
- A low proportion of drugs considered to be amenable to RGT had such titration information described in labeling (39%)
- For drugs in which RGT is described in labeling, slightly more than half (53%) studied a RGT approach in pivotal efficacy trials
- Multiple dosing regimen studies and E/R or D/R were critical for informing RGT for drugs where RGT was not formally evaluated

Barriers and Opportunities


- Barriers to RGT in Clinical Development
 - Increased clinical trial complexity
 - Perceived increased patient inconvenience
 - Paucity of fit-for-purpose biomarkers
 - Population-focused dosing
- Enabling Efforts
 - Biomarker development
 - Technology (e.g., wearables)

FD/

Model-Informed Drug Development: **Current US Regulatory Practice and Future** Considerations

Yaning Wang¹*, Hao Zhu¹, Rajanikanth Madabushi¹, Qi Liu¹, Shiew-Mei Huang¹ and Issam Zineh¹





Policy Development

Dose Optimization

Clinical Trial Design

An Opportune Time for Advancement

Clinical Decision

Support/HIT

Model-informed Drug Development

Real World Evidence

Target Drug Benefit/risk CDS/Software **Timing relative** Labeling **Dx Regulation** TDM Reimbursement Regulation to approval

Summary



- A need for precision dosing has been identified
- 3 contexts exist for evidence generation and implementation
- Goal setting and critical evaluation of challenges and opportunities are warranted
- Science, policy, and implementation may be converging to create space for advancement

Overview of the Day



- 8:30 Session 1: The Need for Precision Dosing and Its Challenges
 - 10:10 Break
 - 10:20 Session 1 Panel
- 11:00 Session 2: Precision Dosing: A Focus on Solutions
 - 12:15 Lunch
 - 1:15 Session 2 Panel
- 1:55 Session 3: Translating Real-World Dosing to Patient Drug Dosing Tools
 - 3:10 Break
 - 3:20 Session 3 Panel
- 4:00 Meeting Summary and Closing Remarks

